<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28152" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Quetiapine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Maan</surname>
            <given-names>Jasdave S.</given-names>
          </name>
          <aff>American University of Antigua</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ershadi</surname>
            <given-names>Mona</given-names>
          </name>
          <aff>Mazandaran University of Medical Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khan</surname>
            <given-names>Israr</given-names>
          </name>
          <aff>Bolan Medical College, Quetta, Pakistan</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jasdave Maan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mona Ershadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Israr Khan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28152.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Quetiapine is FDA approved for schizophrenia, acute manic episodes, and adjunctive treatment for major depressive disorder. Quetiapine is also used for several non-FDA-approved indications, such as generalized anxiety disorder. Quetiapine is available both as extended-release (once-daily dosing) or immediate-release (twice-daily dosing) tablets. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, monitoring, and toxicity of quetiapine, so providers can direct patient therapy successfully in instances where quetiapine provides a benefit to patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the approved and off-label uses for quetiapine.</p></list-item><list-item><p>Describe the adverse effects of quetiapine.</p></list-item><list-item><p>Review the mechanism of action of quetiapine.</p></list-item><list-item><p>Identify the importance of interprofessional communication regarding the adverse effects of quetiapine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28152&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28152">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28152.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Quetiapine is FDA approved for schizophrenia, acute manic episodes, and adjunctive&#x000a0;treatment for major depressive disorder. There is FDA indication through three 6-week trials and one 6-week trial for schizophrenia in adults and adolescents ages 13 to 17.&#x000a0;The first trial showed that in adults, the maximal effect occurred at 300 mg per day. A mean of around 450 mg per day in the second trial showed superiority over placebo, and a mean of&#x000a0; 500 mg per day in the third trial showed superiority over the group that received 50 mg a day. The researchers concluded that the effective range was from 150 mg to 750 mg for treating schizophrenia in adults. In the one six-week trial, the conclusion was that quetiapine, at an average dose of 400 mg/day to 800 mg/day, was superior to the placebo in adolescents. Two 12-week trials showed efficacy for mono-therapeutic effects.</p>
        <p>Treatment for acute manic episodes associated with bipolar I disorder in adults with a majority at a dosing range of 400 mg/day to 800 mg/day. One three-week trial showed that quetiapine was effective as an adjunct treatment for acute manic episodes in bipolar I disorder to lithium or divalproex in adults. One three-week trial showed efficacy at 400 mg/day to 600 mg/day for mono-therapeutic treatment for bipolar I disorder for children and adolescents ages 10 to 17. Two trials showed effectiveness in the acute treatment of depressive episodes in bipolar I and II in adult patients. The drug&#x000a0;showed efficacy at 300 mg/day, and no additional benefits were apparent at a high 600 mg/day dosage.<xref ref-type="bibr" rid="article-28152.r1">[1]</xref> Two maintenance trials showed effectiveness in maintaining bipolar disorder at dosages of 400 mg/day to 800 mg/day.<xref ref-type="bibr" rid="article-28152.r2">[2]</xref><xref ref-type="bibr" rid="article-28152.r3">[3]</xref></p>
        <p>Quetiapine has uses in several non-FDA-approved indications, such as generalized anxiety disorder. Three randomized control trials have shown the efficacy of treatment in mono-therapeutic treatment over placebo. Research on other off-label uses has not been strong enough to advocate FDA approval, and more clinical trials are necessary.<xref ref-type="bibr" rid="article-28152.r4">[4]</xref> Another clinical trial showed effectiveness in the mono-therapeutic treatment of major depressive disorder and as adjunctive with antidepressants. Other non-FDA approved: psychosis in patients with Parkinson's disease, insomnia, maintenance of schizophrenia, and chronic post-traumatic stress disorder (PTSD).<xref ref-type="bibr" rid="article-28152.r5">[5]</xref><xref ref-type="bibr" rid="article-28152.r6">[6]</xref>&#x000a0;Adjunctive treatment with SSRI for obsessive-compulsive disorder (OCD), borderline personality disorder, decreasing aggression with psychiatric illness, major depressive disorder, and symptomatic treatment of insomnia, agitation, and anxiety.<xref ref-type="bibr" rid="article-28152.r7">[7]</xref><xref ref-type="bibr" rid="article-28152.r8">[8]</xref><xref ref-type="bibr" rid="article-28152.r9">[9]</xref>&#x000a0;A limited number of case reports support efficacy in these situations, yet it is&#x000a0;still commonly prescribed for such off-label treatments. For these reasons, clinicians should avoid using long-term treatment as the side effects outweigh the unestablished benefits.</p>
      </sec>
      <sec id="article-28152.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Quetiapine has a strong affinity for the 5-HT2 receptor. Although quetiapine has many complex mechanisms, it mediates its pharmacological effect mainly via its 5HT2 antagonistic action. It also acts on dopaminergic D1 and D2 receptors. Quetiapine is an antagonist for D2 receptors and 5-HT2 receptors.<xref ref-type="bibr" rid="article-28152.r10">[10]</xref>&#x000a0;It is also suggested that the anxiolytic and antidepressant properties of both quetiapine and its active metabolite norquetiapine are due to the norepinephrine transporter (NET) inhibitory potential and partial agonist activity at the 5 HT1A receptor, respectively.<xref ref-type="bibr" rid="article-28152.r11">[11]</xref></p>
        <p>Blocking the D2 receptor in mesocortical and mesolimbic pathways is indicated in the treatment of schizophrenia for negative and positive symptoms, respectively. Increased dopamine in these pathways has been shown to be associated with schizophrenia. Jensen et al. also reported that antidepressant activity is also mediated by its 5HT2A and 5-HT7 antagonistic properties. Furthermore, norquetiapine has an affinity for other receptors, such as H1 histamine receptor, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT7 serotonergic receptors, M1, M3, and M5 muscarinic receptors, and &#x003b1;1-adrenergic receptors.<xref ref-type="bibr" rid="article-28152.r12">[12]</xref></p>
      </sec>
      <sec id="article-28152.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Quetiapine is available both as quetiapine extended-release (ER; once-daily dosing) or quetiapine immediate release (IR; twice to three times daily dosing) tablets. The tablets are available in 25&#x000a0;mg, 50&#x000a0;mg, 100&#x000a0;mg, 200&#x000a0;mg, 300&#x000a0;mg, and 400 mg tablets, with the ER dose formulation available in 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg tablets.&#x000a0;Figueroa et al. also reported that 800 mg/day is the maximum recommended dose for quetiapine IR formulation twice or thrice daily divided doses. After oral administration, it is promptly absorbed and reaches its peak plasma concentration in approximately 1&#x000a0;to 2 hours. The reported half-life (t1/2) for quetiapine is about 7 hours.<xref ref-type="bibr" rid="article-28152.r13">[13]</xref><xref ref-type="bibr" rid="article-28152.r14">[14]</xref><xref ref-type="bibr" rid="article-28152.r15">[15]</xref></p>
        <p>Dosing is as follows (all dosing is oral):</p>
        <p>
<bold>For Schizophrenia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>IR: 150 to 750 mg daily in two or three divided doses; start at 25 mg twice daily, and titrate up to 300 to 800 mg daily in two or three divided doses, with daily increases of 50 to 150 mg. In elderly patients, increase 25 to 50 mg daily.</p>
          </list-item>
          <list-item>
            <p>ER: 400 to 800 mg each evening; start with 300 mg daily with up to 300 mg increases daily&#x000a0;or as needed. In the elderly, start at 50 mg daily with 50 mg dose increments. Patients should not chew, crush, or cut the ER tablets.</p>
          </list-item>
        </list>
        <p>
<bold>For Bipolar I Disorder (manic)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>IR: 200 to 400 mg twice daily. Start at 50 mg twice daily, increasing by 100 mg a day to 200 mg twice daily by the fourth day, then begin increasing by 200 mg each day as needed. The maximum dose is 800 mg daily.</p>
          </list-item>
        </list>
        <p>
<bold>For Bipolar I Disorder (manic/mixed)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>ER: 400 to 800 mg each evening. Start at&#x000a0;300 mg daily for one day, then 600 mg in the evening for one day; adjust by 200 mg per day or as needed to a maximum dose&#x000a0;of 800 mg daily. In the elderly, start with 50 mg in the evening with 50 mg increments daily for therapeutic effectiveness.</p>
          </list-item>
        </list>
        <p>
<bold>For Acute Depressive Bipolar Disorder&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>IR:&#x000a0;300 mg daily at bedtime; start at 50 mg at bedtime for one day, then 100 mg at bedtime for one day, 200 mg at bedtime for one day, then 300 mg at bedtime. The maximum dose is 600 mg daily, with doses over 300 mg daily rarely demonstrating effectiveness. For the elderly, start with 25 mg at bedtime, with 25 to 50 mg dose increases daily.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>ER: 300 at bedtime; start with 50 mg in the evening, then 100 mg&#x000a0;each evening for one day, 200 mg&#x000a0;in the evening for one day, then 300 mg in the evening. The maximum dose is 300 mg daily. In the elderly, start with 50 mg in the evening, with 50 mg daily dose increments. Patients should not chew, crush, or cut the ER tablets.</p>
          </list-item>
        </list>
        <p>As an adjunct treatment measure for various forms of major depressive disorder, the dose ranges from 50 to 300 mg daily with the IR form and 150 to 300 mg daily with the ER form, using similar titration schedules to a maximum of 300 mg daily.</p>
        <p>For efficacy, a range of 300 mg to 800 mg a day should be optimal, and for some patients, prescribers can try a non-FDA-approved dose of 1200 mg to 1600 mg per day for benefits, with QT interval monitoring.</p>
      </sec>
      <sec id="article-28152.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>As with any antipsychotic drug, quetiapine&#x000a0;is associated with an increased risk of death in dementia-related psychosis in elderly patients. Alongside this risk, neuroleptic malignant syndrome should be a consideration due to its D2 receptor blockage. It is the least likely of atypical antipsychotics to cause extrapyramidal symptoms. There is an increased risk for suicidal thoughts and behavior associated with drug treatment in major&#x000a0;depressive disorder patients. Somnolence, orthostatic hypotension, and dizziness are the most common side effects of quetiapine. Somnolence and dizziness are due to the nature of quetiapine&#x02019;s antagonism of H1 receptors, while antagonism causes hypotension for alpha-1 receptors.<xref ref-type="bibr" rid="article-28152.r16">[16]</xref>&#x000a0;Stroke, myocarditis, and coronary heart disease have also correlated with the use of this drug.<xref ref-type="bibr" rid="article-28152.r17">[17]</xref></p>
      </sec>
      <sec id="article-28152.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are currently no known FDA contraindications to quetiapine. However, there are several precautions to be considered when administering this drug. As mentioned before, quetiapine and other atypical antipsychotics are associated with an increased risk of death in elderly patients with dementia-related psychosis. Also, precaution is a consideration with drugs that increase QT intervals and patients with prolonged QT intervals. Drugs include Class I and Class III antiarrhythmics, antipsychotics, macrolides, fluoroquinolone, pentamidine, levomethadyl acetate, methadone, first-, and second-generation antipsychotics, tricyclic antidepressants, quinine, halofantrine, and albendazole. These combinations put the patient at risk for torsades de pointes. Precautions are also necessary for patients with a history of cardiac arrhythmia, hypokalemia, and hypomagnesemia.<xref ref-type="bibr" rid="article-28152.r18">[18]</xref>&#x000a0;The clinician should consider metabolic panels before starting the drug. Patients with diabetes mellitus should have their glucose monitored in an attempt to avoid hyperosmolar coma.<xref ref-type="bibr" rid="article-28152.r19">[19]</xref> Quetiapine is not recommended for breastfeeding women, and a high benefit to risk rationale is necessary for use in pregnant women.<xref ref-type="bibr" rid="article-28152.r17">[17]</xref></p>
      </sec>
      <sec id="article-28152.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The therapeutic range of quetiapine is between 100&#x000a0;ng/mL&#x000a0;to 1000 ng/mL. As mentioned before, patients commonly experience somnolence, dizziness, and orthostatic hypotension. Within this therapeutic range, the patient might experience other common side effects such as tachycardia, dyspnea, cough, pharyngitis, rhinitis and nasal congestion, dry mouth, constipation, dyspepsia, abdominal pain, leukopenia, neutropenia, lethargy, hyperlipidemia, hyperglycemia, peripheral edema, sedation, weight gain, and tardive dyskinesia. Monitor the metabolic panel with a specific focus on fasting glucose, cholesterol and triglyceride levels, blood pressure, and weight. Patients should also receive a lens examination every six months during long-term treatment for cataract monitoring. Agranulocytosis is a very rare but reported side effect associated with quetiapine use.<xref ref-type="bibr" rid="article-28152.r17">[17]</xref></p>
      </sec>
      <sec id="article-28152.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Quetiapine can be life-threatening if abused or misused. Toxicity is associated with levels greater than 1500 ng/mL in serum or plasma. Supportive care is the mainstay of treatment. In acute toxicity, measures are necessary to maintain the airway and ensure adequate oxygenation and ventilation. Gastric lavage and activated charcoal administration alongside a laxative to prevent further drug absorption are used if time appropriate. Plasma concentrations of quetiapine reach maximal levels within 1 to 2 hours of oral administration. ECG is a recommendation to monitor for possible Torsades de pointes or another arrhythmia due to QT-interval prolongation. Treat extrapyramidal effects with anticholinergic and hypotension with intravenous fluids and sympathomimetic agents such as A1 agonists. Management/treatment of neuroleptic malignant syndrome is possible by immediate withdrawal of quetiapine, followed by the management of symptoms.<xref ref-type="bibr" rid="article-28152.r20">[20]</xref><xref ref-type="bibr" rid="article-28152.r21">[21]</xref>&#x000a0;</p>
        <p>Currently, no definitive antidote exists to reverse quetiapine toxicity; however, in a case report, the patient developed toxicity secondary to quetiapine, characterized by hypotension, tachycardia, altered sensorium, and electrocardiogram (ECG) showed a QT interval of 110 milliseconds. After the initial failure of symptomatic management, the patient was treated successfully after administration of Intravenous lipid emulsions (ILEs) (a source of calories and essential fatty acids rendered for patients who do not tolerate enteral nutrition) at a dose of 1.5 mg/kg for up to two doses 15 minutes apart. Rapid improvement was seen in the patient after 30 minutes. It is proposed that it might be because of the lipophilic nature of quetiapine.<xref ref-type="bibr" rid="article-28152.r22">[22]</xref>&#x000a0;Similarly, the beneficial effect of ILE was also reported by Bartos and Knudsen in resuscitating patients with cardiovascular collapse.<xref ref-type="bibr" rid="article-28152.r23">[23]</xref>&#x000a0;Another case series study reported successful reversal of significantly altered mental status with <italic toggle="yes">physostigmine</italic> (a muscarinic agonist).<xref ref-type="bibr" rid="article-28152.r24">[24]</xref></p>
      </sec>
      <sec id="article-28152.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Quetiapine is associated with several potentially dangerous side effects. The nurse,&#x000a0;pharmacist, and clinicians should communicate and work with an interprofessional team&#x000a0;to monitor patients taking this medication. [Level 5]</p>
      </sec>
      <sec id="article-28152.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28152&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28152">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28152/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28152">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28152.s11">
        <title>References</title>
        <ref id="article-28152.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garriga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sol&#x000e9;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Pinto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Selva-Vera</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Arranz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Amann</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Saiz-Ruiz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Blanco</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vieta</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>959</fpage>
            <page-range>959-969</page-range>
            <pub-id pub-id-type="pmid">28882405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suttajit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Srisurapanont</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maneeton</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maneeton</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Quetiapine for acute bipolar depression: a systematic review and meta-analysis.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2014</year>
            <volume>8</volume>
            <fpage>827</fpage>
            <page-range>827-38</page-range>
            <pub-id pub-id-type="pmid">25028535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindstr&#x000f6;m</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lindstr&#x000f6;m</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000f6;istad</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Maintenance therapy with second generation antipsychotics for bipolar disorder - A systematic review and meta-analysis.</article-title>
            <source>J Affect Disord</source>
            <year>2017</year>
            <month>Apr</month>
            <day>15</day>
            <volume>213</volume>
            <fpage>138</fpage>
            <page-range>138-150</page-range>
            <pub-id pub-id-type="pmid">28222360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maneeton</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maneeton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Woottiluk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Likhitsathian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suttajit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boonyanaruthee</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Srisurapanont</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2016</year>
            <volume>10</volume>
            <fpage>259</fpage>
            <page-range>259-76</page-range>
            <pub-id pub-id-type="pmid">26834458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villarreal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hamner</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Ca&#x000f1;ive</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Calais</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Durklaski</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qualls</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial.</article-title>
            <source>Am J Psychiatry</source>
            <year>2016</year>
            <month>Dec</month>
            <day>01</day>
            <volume>173</volume>
            <issue>12</issue>
            <fpage>1205</fpage>
            <page-range>1205-1212</page-range>
            <pub-id pub-id-type="pmid">27418378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sperry</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Malhado-Chang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Duffy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wheelock</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Farias</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Olichney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shahlaie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.</article-title>
            <source>Brain Behav</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>e00639</fpage>
            <pub-id pub-id-type="pmid">28638698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakajima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shinagawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Plitman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nakayama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Graff-Guerrero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mimura</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study.</article-title>
            <source>J Alzheimers Dis</source>
            <year>2017</year>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>263</fpage>
            <page-range>263-272</page-range>
            <pub-id pub-id-type="pmid">28800334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riedel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000d8;stergaard</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Ferrannini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Alfano</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vansvik</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa).</article-title>
            <source>Schizophr Res</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>162</volume>
            <issue>1-3</issue>
            <fpage>162</fpage>
            <page-range>162-8</page-range>
            <pub-id pub-id-type="pmid">25592805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Wehr</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Duchemin</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of antipsychotic prescriptions among patients with anxiety disorders treated in inpatient and outpatient psychiatric settings.</article-title>
            <source>J Affect Disord</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>191</volume>
            <fpage>292</fpage>
            <page-range>292-9</page-range>
            <pub-id pub-id-type="pmid">26688499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saller</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Seroquel: biochemical profile of a potential atypical antipsychotic.</article-title>
            <source>Psychopharmacology (Berl)</source>
            <year>1993</year>
            <volume>112</volume>
            <issue>2-3</issue>
            <fpage>285</fpage>
            <page-range>285-92</page-range>
            <pub-id pub-id-type="pmid">7871032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cross</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Widzowski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maciag</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zacco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hudzik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nyberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models.</article-title>
            <source>Br J Pharmacol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>173</volume>
            <issue>1</issue>
            <fpage>155</fpage>
            <page-range>155-66</page-range>
            <pub-id pub-id-type="pmid">26436896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensen</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Rodriguiz</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Caron</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Wetsel</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Rothman</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>2303</fpage>
            <page-range>2303-12</page-range>
            <pub-id pub-id-type="pmid">18059438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Figueroa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brecher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamer-Maansson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>2009</year>
            <month>Mar</month>
            <day>17</day>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-204</page-range>
            <pub-id pub-id-type="pmid">18948162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schulz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwersen-Bergmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Andresen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schmoldt</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics.</article-title>
            <source>Crit Care</source>
            <year>2012</year>
            <month>Jul</month>
            <day>26</day>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>R136</fpage>
            <pub-id pub-id-type="pmid">22835221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeVane</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Nemeroff</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2001</year>
            <volume>40</volume>
            <issue>7</issue>
            <fpage>509</fpage>
            <page-range>509-22</page-range>
            <pub-id pub-id-type="pmid">11510628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nikolakopoulou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soares-Weiser</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia.</article-title>
            <source>Health Technol Assess</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>43</issue>
            <fpage>1</fpage>
            <page-range>1-218</page-range>
            <pub-id pub-id-type="pmid">28812541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solmi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murru</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pacchiarotti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Undurraga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Veronese</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fornaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stubbs</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Monaco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vieta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seeman</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2017</year>
            <volume>13</volume>
            <fpage>757</fpage>
            <page-range>757-777</page-range>
            <pub-id pub-id-type="pmid">28721057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Shamliyan</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders.</article-title>
            <source>Ann Transl Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>8</issue>
            <fpage>147</fpage>
            <pub-id pub-id-type="pmid">29862236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Kapadia</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Galiveeti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Drugs and hyperglycemia: A practical guide.</article-title>
            <source>Maturitas</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>104</volume>
            <fpage>80</fpage>
            <page-range>80-83</page-range>
            <pub-id pub-id-type="pmid">28923179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruha</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management.</article-title>
            <source>CNS Drugs</source>
            <year>2012</year>
            <month>Jul</month>
            <day>01</day>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>601</fpage>
            <page-range>601-11</page-range>
            <pub-id pub-id-type="pmid">22668123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minns</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Toxicology and overdose of atypical antipsychotics.</article-title>
            <source>J Emerg Med</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>906</fpage>
            <page-range>906-13</page-range>
            <pub-id pub-id-type="pmid">22555052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arslan</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Demir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kavalci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Karakilic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>&#x000c7;elikel</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Treatment of quetiapine overdose with intravenous lipid emulsion.</article-title>
            <source>Keio J Med</source>
            <year>2013</year>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>53</fpage>
            <page-range>53-7</page-range>
            <pub-id pub-id-type="pmid">23708294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Use of intravenous lipid emulsion in the resuscitation of a patient with cardiovascular collapse after a severe overdose of quetiapine.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>501</fpage>
            <page-range>501-4</page-range>
            <pub-id pub-id-type="pmid">23768031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28152.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cole</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Stellpflug</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Ellsworth</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Reversal of quetiapine-induced altered mental status with physostigmine: a case series.</article-title>
            <source>Am J Emerg Med</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>950</fpage>
            <page-range>950-3</page-range>
            <pub-id pub-id-type="pmid">21802878</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
